Abstract Importance After the US Food and Drug Administration approval of zopapogene imadenovec-drba and its recommendation as the first-line treatment for recurrent respiratory papillomatosis (RRP) in the RRP Foundation Position Statement, standard-of-care treatment for adults with RRP is changing. Practical questions arise with real-world implementation for any new treatment previously studied only in clinical trials.
Clint Allen
Bethesda
As seen in:
LinkedIn,
Nature,
Wiley Online Library,
JAMA Network,
BioRxiv,
eLife,
Mondaq,
Cache Valley Daily,
ENTtoday,
Finopotamus
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Clint
Contact Clint, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack